

NCIC CLINICAL TRIALS GROUP

**SUPERFICIAL BLADDER**

GU DISEASE ORIENTED GROUP MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

ROOM: AUSTEN

APRIL 30<sup>TH</sup>, 2011 – 8:00 AM – 9:00 AM

CHAIR: A. SO

**CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

**Learning Objectives:**

- *To understand and address, through clinical and translational research, the disease burden associated with superficial bladder cancer in Canada.*
- *To review recent developments in the understanding of molecular biology and new therapeutics as these relate to superficial bladder cancer.*
- *To update, review, and discuss recent results of clinical studies conducted by the NCIC Clinical Trials Group and/or by national/ international collaborators.*
- *To provide a learning environment supportive to new investigators.*
- *To understand and apply new clinical trial methodologies in the field of clinical research related to superficial bladder cancer.*

---

<b>8:00 am</b>	<b>Welcome</b>	<b>A. So</b>
<b>8:05 am</b>	<b>Report of current superficial bladder cancer clinical trials open in Canada:</b> OGX-427 (CCSRI / NCIC sponsored trial) Other clinical trials in Canada?	<b>A. So</b>
<b>8:15 am</b>	<b>Challenges to the conduct of superficial bladder cancer clinical trials in Canada:</b> Failure of gefitinib trial Optimal patient group to target	<b>All</b>
<b>8:25 am</b>	<b>New study proposals:</b> Metformin FGFR-4 OGX-427 / VSV	<b>M. Pollak P. Black A. So</b>
<b>8:50 am</b>	<b>Future directions</b>	<b>All</b>
<b>9:00 am</b>	<b>Meeting Adjourned</b>	